Did You Know...
...that in the early 1940s GE engineer James Wright was charged with a task of utmost importance to the war effort: develop a cheap substitute for rubber that could be used to produce tires, gas masks and a whole host of military gear. Wright tackled the task diligently -- and wound up inventing Silly Putty.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| RE41148 | Oral pulsed dose drug delivery system A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is ... | 02/23/2010 |
| 7022337 | Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect A fibrate self-emulsifying oral formulation with improved bioavailability when compared to commercially available formulations containing a therapeutically effective dose of fenofibrate, derivative of fenofibrate or mixtures thereof dissolved in a fibrate solubilize... | 04/04/2006 |
| 7011846 | Oral capsule formulation with increased physical stability A formulation for a stabilized capsule for oral administration of a hydrophobic pharmaceutically active agent; comprising a non-aqueous solubilizer selected from 2-pyrrolidone, N-alkylpyrrolidones and combinations thereof; and a capsule stabilizing agent selected fr... | 03/14/2006 |
| 6913768 | Sustained release delivery of amphetamine salts A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type... | 07/05/2005 |
| 6890918 | Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers A pharmaceutical composition comprising an inhibitor of angiotensin converting enzyme and neutral endopeptidase, such as sampatrilat, and at least one bioavailability enhancer such as an organic acid, e.g., ascorbic acid. Such a composition has improved systemic bio... | 05/10/2005 |
| 6838093 | System for osmotic delivery of pharmaceutically active agents An osmotic system for delivering a pharmaceutically active agent which comprises a core portion, a layer portion enclosing the core portion, and a semipermeable wall portion enclosing the core portion and the layer portion. The core portion includes the pharmaceutic... | 01/04/2005 |
| 6814979 | Osmotic drug delivery system Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which com... | 11/09/2004 |
| 6811794 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutical... | 11/02/2004 |
| 6793934 | Solid oral dosage form A pharmaceutical composition comprising a solid carrier containing a liquid selected from the group consisting of a liquid active agent, a liquid enhancer, or a combination thereof. ... | 09/21/2004 |
| 6772801 | Fluidization of particles for encapsulation in oral dosage pharmaceutical products Encapsulated oral dosage pharmaceutical products are produced utilizing a system including a hopper and a dosator, where the hopper receives particles having irregular geometries and sizes greater than about 100 μm for delivery to the dosator. A gaseous fluid is di... | 08/10/2004 |
| 6692767 | Solid solution beadlet Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting p... | 02/17/2004 |
| 6605300 | Oral pulsed dose drug delivery system A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2... | 08/12/2003 |
| 6514532 | Soluble form osmotic dose delivery system Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; b) a single, homogeneous composition within said wall,... | 02/04/2003 |
| 6384020 | Rapid immediate release oral dosage form A pharmaceutical composition comprising lactitol and one or more amphetamine salts in a rapid release formulation.... | 05/07/2002 |
| 6361796 | Soluble form osmotic dose delivery system Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall... | 03/26/2002 |
| 6322819 | Oral pulsed dose drug delivery system A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2... | 11/27/2001 |
| 6287599 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pha... | 09/11/2001 |
| 6284276 | Soluble form osmotic dose delivery system Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semipermeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall,... | 09/04/2001 |
| 6110498 | Osmotic drug delivery system An osmotic drug delivery system, preferably in tablet form, which dispenses a therapeutic agent having limited water solubility in solubilized form. The delivery system comprises a core that is free of swellable polymers and comprises nonswelling solubili... | 08/29/2000 |
| 5952004 | Emulsified drug delivery systems A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof disper... | 09/14/1999 |
| 5948407 | Oral induction of tolerance to parenterally administered non-autologous polypeptides Disclosed is a method for reducing an immune response to a parenterally administered non-autologous antigen in an individual who is immunologically responsive thereto by mucosally administering to the individual an amount of the antigen effective to reduc... | 09/07/1999 |
| 5912013 | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 μg/ml to about 12 μg/ml over at least... | 06/15/1999 |
| 5897876 | Emulsified drug delivery system A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof disper... | 04/27/1999 |
| 5883103 | Oral acyclovir delivery A pharmaceutical preparation for oral acyclovir delivery comprising a stable, hydrophobic emulsion comprising continuous phase of a hydrophobic material selected from the group consisting of a long chain carboxylic acid or ester or alcohol thereof dispers... | 03/16/1999 |
